• Ranran Xia, Nandita Kachru, Divina M Tuazon, Fariedeh Bostan, and Amaris Fuentes.
• Houston Methodist Hospital, Houston, TX.
• J. Cardiothorac. Vasc. Anesth. 2019 Dec 1; 33 (12): 3348-3357.

ObjectiveTo report on postoperative outcomes related to the administration of neostigmine for reversal of nondepolarizing neuromuscular blocking agents in cardiovascular surgery patients, with a specific focus on the duration of postoperative mechanical ventilation as the primary endpoint.DesignA retrospective cohort study design was followed to achieve the study objectives.SettingThis was a single-center, chart review study conducted at a large academic medical center of adult patients post-cardiovascular surgery.ParticipantsPatients were included if they had received a bolus dose of perioperative nondepolarizing neuromuscular blocking agent and underwent one of the targeted cardiovascular surgeries.InterventionsFinal analysis comprised of 175 patients, 95 of whom received neostigmine and 80 who did not receive neostigmine.Measurements And Main ResultsThe primary endpoint was the duration of postoperative mechanical ventilation. When controlling for all covariates, neostigmine use was associated with a 0.34-hour reduction (∼20.4 min) in duration of mechanical ventilation (parameter estimate: 0.66, 95% confidence interval 0.49-0.89; p = 0.0071). More patients who received neostigmine met the early extubation benchmark of less than 6 hours (55 v 34 patients; p = 0.04). Finally, neostigmine use was not found to be associated with increased risk of respiratory complications or postoperative nausea and/or vomiting.ConclusionsThe use of neostigmine was found to have a protective effect on the duration of postoperative mechanical ventilation without increasing the risk of adverse complications.Copyright © 2019 Elsevier Inc. All rights reserved.

32 keywords...

hide…